On Wednesday the Prime Minister of India announced that Rs. 3100 Crore is allocated from the Prime Minister’s Citizen Assistance and Relief in Emergency Situations (PM CARES Fund) towards the ongoing fight against the COVID-19 virus. The nation went it to lockdown starting March 27, which isn’t over yet due to the COVID-19 pandemic. The Trust was incorporated on March 27, which is headed by the Prime Minister and other members are the Finance Minister, Home Minister, Defence Minister. The Prime Minister thanked all the donors for their generosity in contributing towards the Fund which will support India’s fight against coronavirus. The official twitter page of the Prime Minister came out with the message.
For what the fund will be used?
Out of Rs. 3100 crores, Rs. 2000 crores will be used for the purchase of ventilators, Rs. 1000 crores will be used for the welfare of migrant workers and Rs. 100 crores will be used for the development of the vaccine for COVID-19. Yesterday the Prime Minister said about self-reliance and ‘Make in India’, as a part of which 50,000 ventilators ‘Made in India’ will be purchased at a cost of Rs. 2000 crores. These ventilators will be provided to government hospitals in all states and union territories. The states will also be provided with Rs.1000 crore for the welfare of migrant workers from the fund.
The PM CARES fund will be shared between states/union territories based on the following weightage, the population of the state or union territory based on 2011 census, number of COVID-19 cases as on date, and equal weightage for all states/ union territories to assure minimum sum to all the states/ union territories. The funds will be disposed of from the state disaster relief commissioner to District Collector or Municipal councilor of states concerned.
The officials will be using these funds for the purpose of strengthening the infrastructure requirements, accommodation facilities, food expenses, travel expenses for migrant laborers, etc.
The PM CARES fund also allocated Rs. 100 crore for vaccine development, this will be used under the supervision of the principal scientific advisor.
To read about more current news, click here.